Here are the top five stories on Healio.com/OSN last week:
Bimatoprost sustained-release implant reduces IOP in phase 3 study
A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study. Read more.
Netarsudil ophthalmic solution shows positive phase 2 results in Japanese-American population
A pilot phase 2 trial showed Aerie Pharmaceuticals’ netarsudil ophthalmic solution lowered IOP in a Japanese-American population. Read more.
Takeda completes Shire acquisition
The deal was approved by 89.1% of Takeda’s
Uncategorized